- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04175821
Late-term Effects of Hypofractionated Chest Wall and Regional Nodal Irradiation in Patients With Breast Cancer (LEHR)
Dept. of Radiation Oncology, PGIMER, Chandigarh
Study Overview
Status
Intervention / Treatment
Detailed Description
Between January 1990 to December 2007, women with breast cancer who were given radical treatment with mastectomy, systemic therapy and RT at least 10 years ago were included. Eligible patients were recruited from the radiotherapy department record and these were on regular follow-up in the breast clinic. The study was approved by the departmental ethics committee. Clinical, pathological and treatment characteristics were taken from the patient file. Inclusion criteria were: female patients age ≥18 years of age, with invasive carcinoma of the breast, post mastectomy, complete microscopic excision of primary tumour and stage II or III disease treated with locoregional RT. Exclusion criteria were: breast conserving surgery, stage I or IV disease, past history of malignancy except (i) basal cell skin cancer or CIN cervix uteri or(ii) non-breast malignancy if treated with curative intent and at least 5 years disease-free or contralateral breast cancer, including ductal carcinoma in situ (DCIS), irrespective of date of diagnosis. Patients with bilateral breast cancer were also excluded.
Patients were treated in supine position on a breast board with ipsilateral arm abducted to 900. All patients were planned using 2-D fluoroscopic conventional simulator with two tangential fields to the chest wall and a single incident field to the axilla and supraclavicular fossa. Lateral border of supraclavicular fossa was up to deltoid insertion.
Radiotherapy dose delivered was 35Gy/15fractions /3 weeks to the chest wall. Dose was prescribed at mid separation. Bolus was used in all patients on alternate days, that is for 50% of treatment. In patients with positive margins bolus was used daily and a scar boost of 10Gy/4fractions was given. None of the patients had breast reconstruction. Supraclavicular fossa(SCF), axillary chain and internal mammary nodal irradiation (IMNI)6 was done with a single incident field. No posterior axillary field was used. The dose delivered was 40Gy/15fractions/3weeks. All patients were treated on linac or cobalt-60 machine.
A biologically effective dose(BED) of 35Gy/15fractions/3weeks is 75.1Gy in terms of 2Gy per fraction for late effects, 55.1Gy for tumour control, 45Gy for erythema and 42.3Gy for desquamation in case of local radiotherapy. The BED for RNI with this schedule is 90Gy, 65Gy, 52.5Gy and 49Gy for late effects, tumour control, erythema and desquamation, respectively.
Patients were seen by the radiation oncologists with special focus on chest wall fibrosis, telangiectasia, shoulder function, lymphedema, arm pain and sensory symptoms. Late fibrosis was defined grade 1 as barely palpable firmness, grade 2 as definite increased firmness and grade 3 as marked firmness of the chest wall. Telangiectasia was defined grade 1 as <1cm2, grade 2 as 1 cm2-4 cm2 and grade 3 as >4 cm2 area of chest wall. Lymphedema was graded by measuring arm circumference 10cm above and below the medial epicondyle of humerus . For lymphedema and shoulder function, the treated side was compared with the untreated opposite side as a reference. Lymphedema was classified as none, mild, moderate and marked if there was no difference, 0.5-2cm, 2.1-3cm and >3cm difference, respectively in the circumference of the affected and normal arm. If the patient had symptoms of pain in the arm, paresthesia, numbness, weakness, or other sensory symptoms then injury to the brachial plexus was suspected and reported as brachial plexopathy. A four point scale(none, a little, quite a bit, very much ) was used to assess all late effects according to the RTOG LENT SOMA scale. Late lung toxicity was defined grade 1 as asymptomatic or mild symptoms of dry cough, slight radiographic changes; grade 2 as moderate symptomatic fibrosis or pneumonitis (severe cough), low grade fever, patchy radiographic changes; grade 3 as severe symptomatic fibrosis or pneumonitis, dense radiographic changes and grade 4 as severe respiratory insufficiencies, oxygen required of assisted ventilation. Late cardiac toxicity was defined grade 1 as minimal enlargement of cardiosilhoutte (ECS), grade 2 as ECS without pulmonary congestion, grade 3 as ECS pulmonary congestion and grade 4 as ECS with frank pulmonary oedema. All late effects assessment scores were dichotomised as none/mild versus moderate/marked effects.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- invasive carcinoma of the breast, post mastectomy complete microscopic excision of primary tumour and stage II or III disease
Exclusion Criteria:
- breast conserving surgery, stage I or IV disease, past history of malignancy except (i) basal cell skin cancer or CIN cervix uteri or(ii) non- breast malignancy if treated with curative intent and at least 5 years disease-free or contralateral breast cancer, ductal carcinoma in situ (DCIS), bilateral breast cancer
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chest wall fibrosis ("change" is being assessed)
Time Frame: 5, 10 and 15 years
|
Late fibrosis was defined grade 1 as barely palpable firmness, grade 2 as definite increased firmness and grade 3 as marked firmness of the chest wall.
|
5, 10 and 15 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Telengiectasia ("change" is being assessed for all outcomes)
Time Frame: 5, 10 and 15 years
|
Telangiectasia was defined grade 1 as <1cm2, grade 2 as 1 cm2-4 cm2 and grade 3 as >4 cm2 area of chest wall
|
5, 10 and 15 years
|
Lymphedema
Time Frame: 5, 10 and 15 years
|
Lymphedema was graded by measuring arm circumference 10cm above and below the medial epicondyle of humerus .
For lymphedema and shoulder function, the treated side was compared with the untreated opposite side as a reference.
Lymphedema was classified as none, mild, moderate and marked if there was no difference, 0.5-2cm, 2.1-3cm and >3cm difference, respectively in the circumference of the affected and normal arm.
|
5, 10 and 15 years
|
Lung toxicity
Time Frame: 5, 10 and 15 years
|
Late lung toxicity was defined grade 1 as asymptomatic or mild symptoms of dry cough,slight radiographic changes; grade 2 as moderate symptomatic fibrosis or pneumonitis (severe cough), low grade fever, patchy radiographic changes; grade 3 as severe symptomatic fibrosis or pneumonitis, dense radiographic changes and grade 4 as severe respiratory insufficiencies, oxygen required of assisted ventilation.
|
5, 10 and 15 years
|
Cardiac toxicity
Time Frame: 5, 10 and 15 years
|
Late cardiac toxicity was defined grade 1 as minimal enlargement of cardiosilhoutte (ECS), grade 2 as ECS without pulmonary congestion, grade 3 as ECS pulmonary congestion and grade 4 as ECS with frank pulmonary oedema.
All late effects assessment scores were dichotomised as none/mild versus moderate/marked effects.
|
5, 10 and 15 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LEHR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Late Effects of Hypofractionated Radiotherapy in Breast Cancer
-
University of ZurichUniversity Children's Hospital BaselCompletedLate-effects of Childhood CancerSwitzerland
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)CompletedBreast Cancer | Fatigue | Cancer Survivor | Psychosocial Effects of Cancer and Its Treatment | Long-term Effects Secondary to Cancer Therapy in AdultsUnited States
-
Royal Marsden NHS Foundation TrustMalaysia Palm Oil BoardCompletedLong-term Adverse Effects of Radiotherapy for Pelvic CancerUnited Kingdom
-
Oslo University HospitalEuropean Organisation for Research and Treatment of Cancer - EORTCCompletedQuality of Life | Cancer | Xerostomia | Adverse Effects | Late EffectsNorway, Netherlands, Sweden, Germany, United Kingdom, Greece, France, Israel, Italy, Poland
-
Hospital Universitario Reina Sofia de CordobaCompletedDERMATITIS INDUCED BY RADIOTHERAPY IN PATIENTS WHITH BREAST CANCERSpain
-
Shanghai Juncell TherapeuticsShanghai 10th People's HospitalRecruitingBreast Cancer | Advanced Breast Cancer | Treatment Side Effects | Effects of ImmunotherapyChina
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedBreast Cancer | Fatigue | Neurotoxicity | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Long-term Effects Secondary to Cancer Therapy in Adults | Chemotherapeutic Agent ToxicityUnited States
-
Case Comprehensive Cancer CenterTerminatedBreast Cancer | Colorectal Cancer | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its TreatmentUnited States
-
Georgetown UniversityNational Cancer Institute (NCI)CompletedBreast Cancer | Psychosocial Effects of Cancer and Its TreatmentUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedDepression | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Anxiety Disorder | Psychosocial Effects of Cancer and Its Treatment | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States
Clinical Trials on Hypofractionated radiotherapy
-
Maria Sklodowska-Curie National Research Institute...RecruitingRecurrent Soft Tissue Sarcoma | Recurrent Sarcoma | Radiation Induced Neoplasms | Radiation-Induced CancerPoland
-
Hospital da BaleiaUnknownBreast Cancer | Radiation Toxicity
-
University of UtahNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Endometrial CarcinomaUnited States
-
University Hospital HeidelbergRecruitingProstate CancerGermany
-
University of UtahActive, not recruitingStage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In SituUnited States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingBreast CarcinomaChina
-
Medical University of GrazTerminatedProstate Cancer | Radiotherapy Side EffectAustria
-
Sunnybrook Health Sciences CentreCanadian Association of Radiation OncologyCompleted
-
Consorci Sanitari de TerrassaActive, not recruitingProstate Cancer | Faecal IncontinenceSpain
-
Alberta Health servicesCompletedProstate CancerCanada